Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations

LESSONS LEARNED. This single‐arm, phase II study shows that concurrent EGFR‐tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non‐small cell lung cancer harboring EGFR active mutations provides long‐term control for the primary lung lesion, and 1‐year prog...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Zheng, LinPeng, Wang, Yanmei, Xu, Zihan, Yang, Qiao, Zhu, Guangkuo, Liao, Xing‐Yun, Chen, Xiewan, Zhu, Bo, Duan, Yuzhong, Sun, Jianguo
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693693/
https://ncbi.nlm.nih.gov/pubmed/31040256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0285
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky